세계의 수신증 치료제 시장 : 유형별, 적응증별, 진단별, 치료별, 연령대별 예측(2024-2032년)

Global Hydronephrosis Treatment Market will witness 8.2% CAGR between 2024 and 2032, propelled by advancements in research and development within the field. As medical science continues to uncover new insights and technologies, innovative treatment modalities for hydronephrosis are emerging. For instance, in September 2022, researchers at the University of Nevada, Reno, identified two essential ion channels facilitating urine flow from kidneys to ureters. They explored muscle contraction mechanisms from the renal pelvis to the ureters, enhancing comprehension of urine movement. Nathan Grainger, Ph.D., co-author, highlighted the significance of this research for human health, as it aims at developing therapeutics targeting specific ion channels for hydronephrosis treatment.

These developments offer promising solutions for patients suffering from this condition, driving up demand for effective therapies. Moreover, increased awareness among healthcare professionals and patients regarding the importance of early diagnosis and treatment further fuels market growth. With a growing emphasis on patient-centric care and improved outcomes, there's a pressing need for novel treatments that address the underlying causes of hydronephrosis. Consequently, the rising research and development efforts in this field are instrumental in meeting the escalating demand for advanced therapies.

The overall Hydronephrosis Treatment Industry is classified based on the type, indication, diagnosis, treatment, age group, and region.

The extrinsic segment will undergo rigorous development from 2024 to 2032. These conditions, such as tumors, pregnancy, or enlarged organs, can compress the urinary tract, leading to hydronephrosis. As healthcare professionals diagnose and manage such extrinsic causes, there's a concurrent need for effective treatments addressing the resulting hydronephrosis. This demand fuels ongoing research and development efforts to innovate therapeutic interventions capable of alleviating symptoms and preserving renal function. Consequently, the market for hydronephrosis treatments experiences increased demand as it caters to the diverse etiologies contributing to this condition.

The hydronephrosis treatment market share from the bilateral hydronephrosis segment will register a notable CAGR from 2024 to 2032. This condition, characterized by the obstruction of both kidneys, presents unique challenges that drive the need for effective therapeutic solutions. As bilateral hydronephrosis can lead to severe complications such as kidney damage and renal failure, there is a heightened demand for innovative treatment options that can alleviate symptoms and improve patient outcomes. Consequently, the market for hydronephrosis treatments is experiencing increased demand as healthcare providers and patients seek interventions tailored to address the complexities of bilateral hydronephrosis and mitigate its adverse effects on renal function.

Asia Pacific hydronephrosis treatment market will showcase a commendable CAGR from 2024 to 2032. With a growing population and increasing awareness of urological conditions, there is a rising prevalence of hydronephrosis cases in the region. Additionally, improving healthcare infrastructure and access to medical services enable more individuals to seek diagnosis and treatment for this condition. The demand for effective hydronephrosis treatments is further fueled by the region's aging population and changing lifestyle patterns. As a result, manufacturers and healthcare providers are witnessing a significant uptick in demand for innovative therapies tailored to meet the specific needs of patients in the Asia-Pacific region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of kidney diseases
    • 3.2.1.2 Increasing patient population related to urinary tract infections
    • 3.2.1.3 Growing demand for minimally invasive procedures
    • 3.2.1.4 Increasing adoption of advanced imaging techniques for diagnosis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness and high treatment cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis
• 3.9 Epidemiology outlook
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Unilateral hydronephrosis
• 5.3 Bilateral hydronephrosis

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intrinsic
  • 6.2.1 Acute unilateral obstructive uropathy
  • 6.2.2 Kidney stone
  • 6.2.3 Bladder cancer
  • 6.2.4 Bladder stones
  • 6.2.5 Urethral stricture
  • 6.2.6 Pelvic organ prolapse
  • 6.2.7 Other intrinsic indications
• 6.3 Extrinsic
  • 6.3.1 Retroperitoneal fibrosis
  • 6.3.2 Ovarian vein syndrome
  • 6.3.3 Other extrinsic indications

Chapter 7 Market Estimates and Forecast, By Diagnosis, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Laboratory tests
  • 7.2.1 Urinalysis
  • 7.2.2 Complete blood count
  • 7.2.3 Electrolyte analysis
  • 7.2.4 Other laboratory tests
• 7.3 Imaging
  • 7.3.1 Ultrasound
  • 7.3.2 Intravenous pyelography
  • 7.3.3 KUB X-Rays
  • 7.3.4 CT-scan
  • 7.3.5 Other imaging types

Chapter 8 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Shock wave lithotripsy
• 8.3 Laparoscopy
• 8.4 Bladder catheterization
• 8.5 Steroid therapy
• 8.6 Other treatments

Chapter 9 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Adult
• 9.3 Pediatric

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amgen Inc.
• 11.3 The Anthem Group
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Nephrogenex Inc.
• 11.6 Novartis AG
• 11.7 Pfizer Inc.
• 11.8 Phraxis Inc.
• 11.9 Renal Associates P.A.
• 11.10 Sanofi